PhD Programme in Experimental Medicine and Therapy - Dottorato in Medicina e Terapia Sperimentale

1.   Cusato J, Calcagno A, Marinaro L, Avataneo V, DʹAvolio A, Di Perri G, Bonora S. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. Pharmacogenomics J. 2019 [Epub ahead of print] Impact factor: 3.503.

2.   Focà E, Magro P, Guaraldi G, Riva A, Cattelan AM, De Socio GV, Costa C, Piconi S, Celesia BM, Nozza S, Orofino G, Castagna A, Di Perri G, Castelli F, Calcagno A; GEPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO" Cohort. PLoS One. 2019 Oct 17;14(10):e0222225. Impact factor: 2.776.

3.   Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, Calcagno A. The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. J Neurovirol. 2019 Jun 18. [Epub ahead of print] Impact factor: 2.302.

4.   Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Burdino E, Audagnotto S, Mighetto L, Milia MG, Di Perri G, Calcagno A. Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. CNS Spectr. 2019 May 27:1-7. [Epub ahead of print] Impact factor: 3.940.

5.   Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. Antivir Ther. 2019 Apr 12. [Epub ahead of print] Impact factor: 2.140.

6.   Cusato J, Calcagno A, De Nicolò A, Mogyorosi K, D'Avolio A, Di Perri G, Bonora S. Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. Diagn Microbiol Infect Dis. 2019 Jun; 94(2):202-204. Impact factor: 2.314.

7.   Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? Antimicrob Agents Chemother. 2019 May 24;63(6). Impact factor: 4.715.

8.     Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnouvo B, Nakasujja N, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. Oxf Med Case Reports. 2019. Not Impacted.

9.   Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study. Clin Pharmacol Ther. 2019. Impact Factor 2017: 6.544.

10.  Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, Calcagno A, Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. Biomed Rep. 2019. Not Impacted.

11.  Peyracchia M, Verardi R, Rubin SR, Abu-Assi E, Montrucchio C, Perl L, Grossomarra W, Calcagno A, Omedè P, Montefusco A, Bonora S, Moretti C, D'Amico M, Mauro R, D'Ascenzo F. In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. J Cardiovasc Med (Hagerstown). 2019. Impact Factor 2017: 1.67.

12.  Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019;22(1):e25227. Impact Factor 2017: 5.131.

13.  Lupia T, Costa C, Forni N, Calcagno A. A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. G Ital Dermatol Venereol. 2019. Impact Factor 2017: 1.327.

14.  Bertero L, Joseph SB, Trunfio M, Allice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1 infected participants. AIDS. 2019.Impact Factor 2017: 4.914.

15.  Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2018. Impact Factor 2017: 5.217.

16.  Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, Monforte AD, D'Ettorre G, Antinori A, Calcagno A. Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? AIDS. 2018. Impact Factor 2017: 4.914.

17.  Di Perri G, Calcagno A, Trentalange A, Bonora S. The clinical pharmacology of integrase inhibitors. Expert Rev Clin Pharmacol. 2018. Impact Factor 2017: 2.758.

18.  Calcagno A, Fiumanò M, Zugna D, Cusato J, Montrucchio C, Marinaro L, Trentini L, Ferrara M, D'Avolio A, Pizzi C, Di Perri G, Bonora S. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? Pharmacogenomics J. 2019;19(1):65-71. Impact Factor 2017: 3.812.

19.  von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. J Antimicrob Chemother. 2019;74(1):135-138. Impact Factor 2017: 5.217.

20.  Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, Calcagno A. Cerebral white matter Hyperintensities in HIV-positive patients. Brain Imaging Behav. 2018. Impact Factor 2017: 3.719.

21.  Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018. Not Impacted.

22.  Merlini E, Iannuzzi F, Calcagno A, Bai F, Trunfio M, d'Arminio Monforte A, Bonora S, Marchetti G. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). J Neurovirol. 2018 Jul 9. doi: 10.1007/s13365-018-0661-1. [Epub ahead of print] Impact Factor 2016: 3.206.

23.  Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, Calcagno A, Di Perri G. Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. Infez Med. 2018 Jun 1;26(2):160-163. Not Impacted.

24.  Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, Calcagno A. Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. J Clin Pharmacol. 2018 Jun 6. doi: 10.1002/jcph.1266. [Epub ahead of print] Impact factor 2017: 2.881.

25.  Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Med. 2018 Jun 4. doi: 10.1111/hiv.12624. [Epub ahead of print] Impact factor 2017: 2.932.

26.  Peyracchia M, De Lio G, Montrucchio C, Omedè P, d'Ettore G, Calcagno A, Vullo V, Cerrato E, Pennacchi M, Sardella G, Manga P, GrossoMarra W, Vullo F, Fedele F, Biondi-Zoccai G, Moretti C, Vachiat A, Bonora S, Rinaldi M, Mancone M, D'Ascenzo F. Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. Atherosclerosis. 2018 Jul;274:218-226. doi: 10.1016/j.atherosclerosis.2018.05.001. Epub 2018 May 5. Impact factor 2017: 4.467.

27.  Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A. Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. HIV Med. 2018 May 15. doi: 10.1111/hiv.12622. [Epub ahead of print] Impact factor 2017: 2.932.

28.  Focà E, Calcagno A, Bonito A, Cusato J, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Castelnuovo F, Di Perri G, Castelli F, Bonora S. Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00309-18. doi: 10.1128/AAC.00309-18. Print 2018 Jul. Impact factor 2017: 4.255.

29.  Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. BMC Geriatr. 2018 Apr 20;18(1):99. doi: 10.1186/s12877-018-0789-0. Impact factor 2017: 2.866.

30.  Calcagno A, Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, Tempestilli M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. Br J Clin Pharmacol. 2018 Feb 14. doi: 10.1111/bcp.13552. [Epub ahead of print] Impact factor 2016: 3.493.

31.   Bigliano P, Calcagno A, Lucchini A, Audagnotto S, Montrucchio C, Marinaro L, Alcantarini C, Ghisetti V, Di Perri G, Bonora S. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. Antivir Ther. 2018 Jan 26. doi: 10.3851/IMP3221. [Epub ahead of print] Impact factor 2016: 2.594.

32.   Calcagno A, Barco A, Trunfio M, Bonora S. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. Curr HIV/AIDS Rep. 2018 [Epub ahead of print] Impact factor 2016: 4.038.

33.   Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolò A, Alcantarini C, D'Avolio A, Bonora S, Di Perri G, Calcagno A. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. J Antimicrob Chemother. 2017. [Epub ahead of print] Impact factor 2016: 5.071.

34.   Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. J Neurovirol. 2017 [Epub ahead of print] Impact Factor 2016: 3.206.

35.   Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Expert Opin Drug Metab  Toxicol. 2018;14(1):59-82. Impact Factor 2016: 3.027.

36.   Cusato J, Allegra S, Nicolò A, Calcagno A, D'Avolio A. Precision medicine for HIV: where are we? Pharmacogenomics. 2018 Jan;19(2):145-165. Impact factor 2016: 2.350.

37.   Motta I, Trunfio M, Calcagno A, Pirriatore V, Scabini S, Palazzo A, Audagnotto S, Fatiguso G, Liberini V, Bellò M, D'Avolio A, Di Perri G, Bonora S. Undetectable antimicrobial plasma concentrations in an HIV-positive patient with  protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. J Antimicrob Chemother. 2017 [Epub ahead of print] Impact factor 2016: 5.071.

38.   Focà E, Calcagno A, Bonito A, Simiele M, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. J Antimicrob Chemother. 2017;72(11):3163-3166. Impact factor 2016: 5.071.

39.    Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-infected Patient. J Acquir Immune Defic Syndr. 2017 [Epub ahead of print]. Impact factor 2016: 3.935.

40.    Mornese Pinna S, Scarvaglieri E, Milia MG, Imperiale D, Ghisetti V, Audagnotto S, Prochet A, Lipani F, Bonora S, Di Perri G, Calcagno A. Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? J Neurovirol. 2017 [Epub ahead of print] Impact factor 2016: 3.206.

41.    Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPPO Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother. 2017 [Epub ahead of print] Impact factor 2016: 5.071;

42.    Allegra S, Fatiguso G, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Di Perri G, D'Avolio A. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. Pharmacogenomics. 2017;18(9):865-880. [Epub ahead of print]. Impact factor 2016: 2.350;

43.    Calcagno A, Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglià G, Ghisetti V, Di Perri G, Bonora S. High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. Curr HIV Res. 2017 [Epub ahead of print]. ]. Impact factor 2016: 1.612;

44.    Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol. 2017;40(2):86-98. Impact factor 2016 1.720.

45.    Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL. Infection. 2017 [Epub ahead of print]. Impact factor 2016: 2.468;

46.    Calcagno A, Pagani N, Ariaudo A, Arduino G, Carcieri C, D'Avolio A, Marinaro L, Tettoni MC, Trentini L, Di Perri G, Bonora S. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. J Antimicrob Chemother. 2017. [Epub ahead of print]. Impact factor 2016: 5.071.

47.   Biagini R, Montrucchio C, Calcagno A, Trentini L, Tettoni MC, Alcantarini C, Barco A, Trentalange A, Milesi M, Ferrara M, Bertucci R, Di Perri G, Bonora S. Geriatrics in HIV infection: multimorbidity, polipharmacy and primary prevention in patients above 65 years). Journal of HIV and Ageing. 2017;1:19-25. Not Impacted

48.    Motta I, Allice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, Ghisetti V, Di Perri G, Bonora S, Calcagno A.Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. Antivir Ther. 2017 [Epub ahead of print]. Impact factor 2015: 2.910;

49.    Motta I, Calcagno A, Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. Br J Clin Pharmacol. 2017. [Epub ahead of print] Impact factor 2015: 3.830;

50.   Montrucchio C., Biagini R., Alcantarini C., Calcagno A., Barco A., Ferrara M., Milesi M., Costa C., Trentalange A., Trunfio M., Tettoni M. C., Grosso Marra W., D’Ascenzo F., Ballocca F., Lonni E., Gili S., Vai D., Imperiale D., Gaita F., Bonora S., Di Perri G. Cardiovascular risk and neurocognitive deficits in HIV-positive individuals. Infectious Diseases & Tropical Medicine 2017; 3 (1): e370. Not Impacted.

51.    Calcagno A, Di Perri G, Bonora S. Treating HIV Infection in the Central Nervous System. Drugs. 2017 [Epub ahead of print] Impact factor 2015: 4.883;

52.    Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. J Antimicrob Chemother. 2016 [Epub ahead of print] Impact factor 2016: 5.071;

53.    Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, Salassa B, Bramato C, Orofino G, D'Avolio A, Rizzi M, Di Perri G, Rusconi S, Bonora S.Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. J Clin Virol. 2016;87:30-36. Impact factor 2015:2.647;

54.    Guaraldi G, Menozzi M, Zona S, Calcagno A, Silva AR, Santoro A, Malagoli A, Dolci G, Mussi C, Mussini C, Cesari M, Khoo SH. Impact of polypharmacy on antiretroviral prescription in people living with HIV. J Antimicrob Chemother. 2016 [Epub ahead of print] Impact factor 2015: 5.071;

55.    Calcagno A, Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, Scarvaglieri E, Lipani F, Imperiale D, Di Perri G, Bonora S. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. J Neuroimmune Pharmacol. 2016 [Epub ahead of print] Impact factor 2015: 3.896;

56.    Sanfilippo C, Nunnari G, Calcagno A, Malaguarnera L, Blennow K, Zetterberg H, Di Rosa M. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). Virus Res. 2016; 227:220-230. Impact factor 2015: 2.526;

57.    Calcagno A, Cusato J, D'Avolio A, Bonora S. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. Clin Pharmacokinet. 2016 [Epub ahead of print] Impact factor 2015: 4.829;

58.    Gili S, Mancone M, Ballocca F, Grosso Marra W, Calcagno A, D'Ettorre G, Cannillo M, D'Ascenzo F, Orofino G, Marruncheddu L, Lonni E, Cinque A, Vullo F, Ceccarelli G, Vilardi I, Sardella G, Vullo V, Moretti C, Fedele F, Bonora S, Gaita F. Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. J Cardiovasc Med (Hagerstown). 2016 [Epub ahead of print] Impact factor 2015: 1.658;

59.    Ruggiero T, Burdino E, Calcagno A, Bonora S, Boglione L, Di Perri G, Ghisetti V. HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing. Infection. 2016 [Epub ahead of print] Impact factor 2015: 2.294;

60.    d'Arminio Monforte A, Cozzi-Lepri A, Maggiolo F, Rizzardini G, Manconi PE, Gianotti N, Quirino T, Pinnetti C, Rusconi S, De Luca A, Antinori A; Icona Foundation Study cohort. Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS One. 2016;11(6):e0156360. Impact factor 2015: 3.54

61.    Focà E,  Nunnari G,  Calcagno, A. The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities. Future Virology 2016; 11(4):239-243. Impact factor 2014: 1.011.

62.    Patti F, Calcagno A, Simiele M, Bonasso M, Di Perri G, D'Avolio A, Bonora S. Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. Am J Health Syst Pharm. 2016;73(11):750-4. Impact factor 2014: 1.882.

63.    Calcagno A, Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? Pharmacogenomics. 2016 Apr 4. [Epub ahead of print]. Impact factor 2014: 3.218.

64.    Calcagno A, Simiele M, Motta I, Mornese Pinna S, Bertucci R, D'Avolio A, Di Perri G, Bonora S. Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. AIDS Res Hum Retroviruses. 2016 [Epub ahead of print]. Impact factor 2014: 2.325.

65.    Ballocca F, Gili S, D'Ascenzo F, Marra WG, Cannillo M, Calcagno A, Bonora S, Flammer A, Coppola J, Moretti C, Gaita F. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. Prog Cardiovasc Dis. 2016 [Epub ahead of print] Impact factor 2014: 2.418.

66.    Trentalange A, Calcagno A, Ghisetti V, Atzori C, Busolli P, Bonora S, Imperiale D. Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. Antivir  Ther. 2016. [Epub ahead of print]. Impact factor 2014: 3.020.

67.    Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omedè P, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita F. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016. [Epub ahead of print]. Impact factor 2014: 15.203.

68.    Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R, Carosella S, Calcagno A, Audagnotto S, Barbui AM, Brossa S, Ghisetti V, Dal Conte I, Caramello P, Di Perri G. Louseborne Relapsing Fever among East African Refugees, Italy, 2015. Emerg Infect Dis. 2016;22(2):298-301. Impact factor 2014: 6.750.

69.    Cusato J, Tomasello C, Simiele M, Calcagno A, Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2015. [Epub ahead of print] Impact factor 2014: 4.296.

70.    Motta I, Calcagno A, Baietto L, D'Avolio A, De Rosa FG, Bonora S. A probable drug-to-drug interaction between voriconazole and haloperidol in a slow CYP2C9 metabolizer. Infez Med. 2015;23(4):367-9. Not impacted.

71.    Bonora S, Calcagno A, Trentalange A, Perri GD. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. Expert Opin Pharmacother. 2015 Dec 5. [Epub ahead of print] Impact factor 2014: 3.534.

72.    Fatiguso G, Allegra S, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Perri GD, D'Avolio A. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. Int J Pharm. 2015 Nov 28. [Epub ahead of print] Impact factor 2014: 3.650

73.   Calcagno A., Rostagno R., Arnaudo I., Zanusso G., Bonora S., Lucchini A., Maiello A., Dal Conte I., Meoli I., Ferrari S., Monaco S., Rizzuto N., Di Perri G. CSF 14-3-3 protein and its ζ isoform are prognostic markers in HIV positive patients with CNS disease. Infectious Diseases & Tropical Medicine 2015; 1 (2): e92. Not Impacted.

74.    Calcagno A, Cusato J, Marinaro L, Simiele M, Lucchiari M, Alcantarini C, Tettoni MC, Trentini L, Mengozzi G, D'Avolio A, Di Perri G, Bonora S. Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment. AIDS. 2016;30(6):915-20. Impact factor 2014: 5.554.

75.    Livelli A, Orofino GC, Calcagno A, Farenga M, Penoncelli D, Guastavigna M, Carosella S, Caramello P, Pia L. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. Front Behav Neurosci. 2015 Nov 16;9:306. eCollection 2015. Impact factor 2014: 3.300.

76.    Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol. 2015 Jul;38(3):299-328. Impact factor 2014: 1.784.

77.    Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A,Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F,Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V,Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update onintegrase inhibitors: new opportunities for a personalized therapy? The NEXTaimProject. New Microbiol. 2015 Nov;38(4):443-490.Impact factor 2014: 1.784.

78.    Calcagno A, Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, Simiele M, D'Avolio A, Di Perri G, Bonora S. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. Pharmacogenomics J. 2015 Oct 6. doi: 10.1038/tpj.2015.71. [Epub ahead of print]Impact factor 2014: 4.229.

79.    Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S.Raltegravir plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-positive Patients: Safety, Efficacy and Pharmacokinetics. Curr HIV Res. 2015 Sep 29. [Epub ahead of print].Impact factor 2014: 1.757.

80.    Calcagno A, Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC,Trentini L, Di Perri G, DʼAvolio A, Bonora S. Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. Ther Drug Monit. 2015;37(5):695-6.Impact factor 2014: 2.376.

81.    Calcagno A, Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, Montrucchio C,Imperiale D, Di Perri G, Bonora S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. J Neurovirol. 2015. [In Press] Impact factor 2014: 2.595.

82.    Siccardi M, Olagunju A, Simiele M, D'Avolio A, Calcagno A, Di Perri G, Bonora S, Owen A. Class-specific relative genetic contribution for key antiretroviral drugs. J Antimicrob Chemother. 2015. [In Press] Impact factor 2014: 5.313.

83.    Bonora S, Rusconi S, Calcagno A, Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G.Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). J Antimicrob Chemother. 2015 [In Press] Impact factor 2014: 5.313.

84.    Calcagno A, Motta I, Ghisetti V, Lo Re S, Allice T, Marinaro L, Milia MG, Tettoni MC, Trentini L, Orofino G, Salassa B, Di Perri G, Bonora S. HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients. AIDS Res Hum Retroviruses. 2015 [In Press] Impact factor 2014: 2.325.

85.    Calcagno A, D’Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of Raltegravir and Experience from Clinical Trials in HIV-positive Patients. Expert Opinion On Drug Metabolism and Toxicology 2015; 11(7):1167-76.  Impact factor 2013: 2.934.

86.    Baietto L, Calcagno A, Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S,D'Avolio A. A UPLC-MS-MS method for the simultaneous quantification of first-lineantituberculars in plasma and in PBMCs. J Antimicrob Chemother. 2015 [In Press] Impact factor 2014: 5.313.

87.    Simiele M, Carcieri C, De Nicolò A, Ariaudo A, Sciandra M, Calcagno A, Bonora S, Di Perri G, D'Avolio A. A LC-MS method to quantify tenofovir urinaryconcentrations in treated patients. J Pharm Biomed Anal. 2015;114:8-11.Impact factor 2013: 2.829.

88.    Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV,Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV: amultidisciplinary review. Infection. 2015 May 19. [Epub ahead of print]Impact factor 2013: 2.864.

89.    Cerrato E, Calcagno A, D'Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, Demarie D, Omedè P, Abbate A, Bonora S, DiNicolantonio JJ, Estrada V, Escaned J, Moretti C, Gaita F.Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart. 2015;2(1):e000174. Not Impacted.

90.    D'Ascenzo F, Cerrato E, Calcagno A, Grossomarra W, Ballocca F, Omedè P, Montefusco A, Veglia S, Barbero U, Gili S, Cannillo M, Pianelli M, Mistretta E, Raviola A, Salera D, Garabello D, Mancone M, Estrada V, Escaned J, De Marie D, Abbate A, Bonora S, Zoccai GB, Moretti C, Gaita F. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. Atherosclerosis 2015;240(1):197-204[Epub ahead of print]Impact factor 2013: 3.971.

91.    Ghisetti V, Calcagno A, Burdino E, Orofino G, Bonora S. Acute HIV infection:Improved algorithms for HIV testing. J Clin Virol 2015;63:51-2. Impact factor 2013: 3.466.

92.    Calcagno A, Motta I, Milia M, Rostagno R, Simiele M, Libanore V, Fontana S, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Dried Plasma/Blood Spots forMonitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: aCross-sectional Study in Rural Burundi. Br J Clin Pharmacol 2015; 79(5):801-8 Impact factor 2013: 3.688.

93.    Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D’Avolio A and Bonora S.Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. Clin Infect Dis 2015;60(2):311-7.Impact factor 2013: 9.416.

94.    Baietto L, D'Avolio A, Cusato J, Pace S, Calcagno A, Motta I, Corcione S, Di Perri G, De Rosa FG.Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. J Antimicrob Chemother. 2014;70(1):307-8.Impact factor 2014: 5.313.

95.    Calcagno A, Di Perri G, Bonora S.Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System. Clinical Pharmacokinetics 2014. 2014;53(10):891-906.  Impact factor 2013: 5.486;

96.    Trentalange A, Calcagno A, Raviolo S, Prochet A, Audagnotto S, Ghisetti V, Di Perri G and Bonora S. Cytomegalovirus Central Nervous System Compartmentalization in a Patient Presenting with AIDS. Antiviral therapy 2014.[Epub ahead of print]  Impact factor 2013: 3.143;

97.    Bonora S, Calcagno A, Viganò O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D’Avolio A, Mercadante S, Galli M, Di Perri G and Rusconi S. Efficacy, Tolerability and Virological Consequences of Long-term Use of Unboosted Atazanavir plus 2 NRTIs in HIV-infected Patients. Current HIV Research 2014;12(5):339-46.Impact factor 2013: 2.135;

98.    Calcagno A, Baietto L, Pagani N, Simiele M, Audagnotto S, D'Avolio A, De Rosa FG, Di Perri G and Bonora S.Voriconazole and Atazanavir: a CYP 2C19-dependant Manageable Drug to Drug Interaction. Pharmacogenomics 2014;15(10):1281-6.Impact factor 2013: 3.425;

99.    Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, Calcagno A, Omedè P,Bonora S, Mancone M, Vizza D, DiNicolantonio JJ, Pianelli M, Barbero U, Gili S,Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, ZoccaiGB, Moretti C, Gaita F. Heart failure in patients with human immunodeficiencyvirus: a review of the literature. J Cardiovasc Med (Hagerstown) 2014;16(5):383-9.Impact factor 2012:1.407

100. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Di Perri G, Concia E.Disappearance of renal stones in a HIV-1-infected patient after reduction ofatazanavir dose. AIDS Res Hum Retroviruses 2014;30(9):835-6.  Impact factor 2013:2.57

101. D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, SciandraM, Trentini L, Di Perri G, Bonora S. Intracellular accumulation ofatazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 andPXR genetic polymorphisms. J Antimicrob Chemother. 2014. [Epub ahead of print]  Impact factor 2014: 5.313.

102. D'Ascenzo F, Quadri G, Cerrato E, Calcagno A, Omedè P, Grosso Marra W, Abbate A, Bonora S, Biondi Zoccai G, Moretti C, Gaita F. A meta-analysis investigatingincidence and features of stroke in HIV-infected patients in the highly activeantiretroviral therapy era. J Cardiovasc Med (Hagerstown). 2014. [Epub ahead of print]  Impact factor 2013:1.407;

103. Calcagno A, Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S,Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors ofblood-brain barrier damage in the HAART era. J Neurovirol. 2014;20(5):521-5. Impact factor 2014:2.595.

104. D’Ascenzo F, Cerrato E, Appleton D, Moretti C, Calcagno C, Abouzaki N, Vetrovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, Kastrati A, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, DiNicolantonio JJ, Omedè P, Bonora S, Gaita F, Abbate A, Biondi Zoccai G. Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients With Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. Thrombosis Research. 2014;134(3):558-64. Impact factor 2013:2.427.

105. Calcagno A, Marinaro L, Nozza S, Aldieri C, Carbone A, Ghisetti V, Trentalange A, D’Avolio A, Castagna A, Di Perri G and Bonora S. Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. Antiviral Res. 2014.108: 44-7 Impact factor 2013: 3.434.

106. Calcagno A, Lamorde M, D’Avolio A and Bonora S.Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa. Current Pharmacogenomics and Personalized Medicine. 2014;12(1):1-14 Not Impacted

107. De Nicolò A, Simiele M, Calcagno A, Abdi AM, Bonora S, Di Perri G and D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. Antimicrob Agents Chemother. 2014;58(7):4042-7.Impact factor 2012: 4.565.

108. Calcagno A, Nozza S, Simiele M, Milia MG, Chiappetta S, D'Avolio A, Ghisetti V, Lazzarin A, Di Perri G, Bonora S. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.J Antimicrob Chemother. 2014;69(9):2586-8. Impact factor 2013: 5.313.

109. De Nicolò A, Simiele M, Calcagno A, Mohamed Abdi A, Bonora S, Di Perri G, D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. Antimicrob Agents Chemother. 2014. 58(7): 4042-7. Impact factor 2013:4.451.

110. Corcione S, Cardellino CS, Calcagno A, Fossati L, Costa C, Cavallo R, Di Perri G, De Rosa FG. Health-care Associated KPC-BSI: The Time Has Come. Clin Infect Dis. 2014. 59(2);321-2. Impact factor 2013: 9.416;

111. Salizzoni S, D'Ascenzo F, Moretti C, Bonora S, Calcagno A, Omedè P, Montrucchio C, Cerrato E, Colaci C, Sheiban I, Marra S, Rinaldi M, Gaita F Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV. World J Clin Cases. 2014;2(4):97-9. Not Impacted

112. Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC Infect Dis. 2014;14(1):79. Impact factor 2013: 2.561.

113. Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D’Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. J Antimicrob Chemother. 2014 69(5);1436-9. Impact factor 2013: 5.313.

114. De Francia S, Dʼavolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, Calcagno A, Di Perri G, Saglio G. Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. Ther Drug Monit. 2014; 36(3):410-2. Impact factor 2013: 1.926.

115. Calcagno A, D’Avolio A, Di Perri G and Bonora S. Comment on “Higher CNS Penetration-Effectiveness of Long-term Conbination Antiretrovirsal therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid”. J Acquir Immune Defic Syndr. 2013; 62(4):e118-9. Impact factor 2013: 4.394.

116. Calcagno A, Cusato J, Simiele M, et al. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother. 2014; 69(1): 241-5.Impact factor 2013: 5.313.

117. Ruggiero T, De Rosa F, Cerutti F, Pagani N, Allice T, Stella ML, Milia MG, Calcagno A, Burdino E, Gregori G, Urbino R, Di Perri G, Ranieri MV, Ghisetti V. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. Influenza Other Respi Viruses. 2013; 7(6):1416-26. Impact factor 2013:1.895;

118. Calcagno A, Baietto L, Pagani N, et al. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. Scand J Infect Dis. 2013; 45(11):882-884. Impact factor2013: 1.640

119. D’Avolio A, Cusato J, Calcagno A and Di Perri G. Estimating Ribavirin plasma exposure: genetics or therapeutic drug monitoring?J Hepatol. 2013; 59 (3):633-4. Impact factor2013:10.401

120. Calcagno A, Trentini L, Marinaro L, Montrucchio C, D'Avolio A, Ghisetti V, Di  Perri G, Bonora S. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. J Antimicrob Chemother. 2013; 68(8): 1938-9.Impact factor 2013: 5.439;

121. Calcagno A, Nozza S, de Requena DG, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. J Antimicrob Chemother. 2013; 68(7): 1686-8.Impact factor 2013: 5.439;

122. Calcagno A, Boglione L, De Rosa FG, Di Perri G, Bonora S. Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. Clin Infect Dis. 2013; 56(11):1677-8.Impact factor 2013: 9.416

123. Calcagno A, Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni M, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function.Antimicrob Agents Chemother. 2013; 57(4):1840-3.Impact factor 2013: 4.451

124. Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Impact of pre-therapy viral load on virological response to modern first-line HAART. Antivir Ther.2013; 18(7): 867-876. Impact factor 2013: 3.143

125. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, Castagno D, Omedè P, Quadri G, Sciuto F, Presutti D, Frati G, Bonora S, Moretti C, Gaita F. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J. 2013; 34(19): 1432-6. Impact factor 2013: 14.723.

126. Calcagno A, Tettoni MC, Simiele M, Trentini L, Montrucchio C, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. J Antimicrob Chemother 2013. 68(2): 482-4. Impact factor 2013: 5.439;

127. Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Abelö A. External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. AAPS J. 2013; 15(2): 308-15.Impact factor 2012: 4.386;

128. D'Avolio A, Simiele M, Calcagno A, Siccardi M, Larovere G, Agati S, Baietto L, Cusato J, Tettoni M, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J Antimicrob Chemother. 2012; 68(4): 907-10. Impact factor 2012: 5.338;

129. D’avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. Ther Drug Monit 2012; 34(6):722-8. Impact factor 2012: 2.234;

130. Calcagno A, Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;367(9):877-8. Impact factor 2012: 51.658;

131. Bibas M, Lorenzini P, Cozzi-Lepri A, Calcagno A, di Giambenedetto S, Costantini A, Castagna A, Manfrin V, Monforte AD, Antinori A; for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients.AIDS. 2012; 26(16):2107-10. Impact factor 2012: 6.407;

132. Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, Marinaro L, D'Avolio A, Di Perri G, Bonora S. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS. 2012;26(12):1529-33. Impact factor 2012: 6.407;

133. D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, Calcagno A, Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. J Pharm Biomed Anal. 2012;66:376-80. Impact factor 2012: 2.947;

134. Calcagno A, D’Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S and Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spots Devices. British Journal of Clinical Pharmacology 2012;74(1):134-40. Impact factor 2012:  3.578;

135. D’Avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Aguilar Marucco D, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Cusato J, Troshina M, Bonora S, Rizzetto M and Di Perri G. ITPA polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anaemia in patients under standard anti-HCV treatment Therapeutic Drug Monitoring 2012;34(2):165-70. Impact factor 2012: 2.234;

136. Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D’Avolio A, §Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A and Di Perri G. Short Term Additional Enfuvirtide Therapy is Associated with a Greater Immunological Recovery in HIV Very Late Presenters: a Controlled Pilot Study. Infection 2012;40(1):69-75.Impact factor 2012: 2.440;

137. Siccardi M, D’Avolio A, Rodriguez-Novoa S, Simiele M, Baietto L, Calcagno A, Moss D, Back D, Owen A, Bonora S and Di Perri G. Intra and inter patient pharmacokinetic variability of raltegravir in the clinical setting. Therapeutic Drug Monitoring 2012;34(2):232-5. Impact factor 2012: 2.234.

138. D’Avolio, Ciancio A, Siccardi M, Baietto L, Simiele M, Cariti G, Calcagno A, Smedile A, Cusato J, Bonora S, Rizzetto M and Di Perri G. Ribavirin Pharmacokinetics and IL28 plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV ¼ infected patients. Hepatology 2011; 54(6):2278-9. Impact factor 2011: 11.665;

139. Calcagno A, Bonora S, Simiele M, Rostagno R, Tettoni MC, Bonasso M, Romito A, Imperiale D, D’Avolio A and Di Perri G. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. AIDS 2011; 25(11):1437-9. Impact factor 2011: 6.245;

140. Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D’Avolio A, Lazzarin A and Di Perri G. Pharmacokinetics of the Raltegravir/Maraviroc/Etravirine Combination. J Antimicrob Chemother 2011; 66(8):1932-4.Impact factor 2011: 5.068;

141. Bonora S, Gonzalez de Requena D, D’Avolio A, Calcagno A, Tettoni MC, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Pharmacokinetics of switching unboosted Atazanavir co-administered with Tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Antiviral Therapy 2011; 16(4): 499-504. Impact factor 2011: 3.161;

142. Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J Antimicrob Chemother 2011; 66(1): 192-200. Impact factor 2011: 5.068;

143. Calcagno A, Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. J Antimicrob Chemother 2011; 66(1):224-5 Impact factor 2011: 5.068;

144. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Vento S. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients. Braz J  Infect Dis. 2011; 15(5):498-500. Impact factor 2011:  1.005;

145. Siccardi M, D’Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan W, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521C>T polymorphism. Pharmacogenet Genomics. 2010; 20(12):759-65.Impact factor 2010: 3.865;

146. Calcagno A, Rostagno R, Audagnotto S, D'Avolio A, Bonora S, Ghisetti V, Di Perri G. Is peritoneal fluid a sanctuary site for HIV? J Antimicrob Chemother 2010; 65(9):2052-3. Impact factor 2010: 4.659;

147. Calcagno A, Bonora S, D'Avolio A, Siccardi M, Simiele M, Chiesa M, Gonzalez de Requena D, Di Perri G. Raltegravir penetration in seminal plasma of healthy volunteers. Antimicrob Agents Chemother 2010; 54(6):2744-5. Impact factor 2010: 4.672;

148. Calcagno A, Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS 2010; 24(6):931-2. Impact factor 2010: 6.348;

149. Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once-daily dose enough? J Antimicrob Chemother 2010; 65(3):595-7. Impact factor 2010: 4.659;

150. Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Lanzafame M, Penco G, Di Perri G. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. J Acquir Immune Defic Syndr. 2009; 52(3):431-2. Impact factor 2009: 4.207;

151. Bonora S, Calcagno A, Di Perri G. HIV infection: treatment of naïve patients. Infez Med. 2009; 17(2):69-81. Not Impacted.

152. Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol. 2009; 81(3):400-5. Impact factor 2009:2.470;

153. Bonora S, Mondo A, Trentini L, Calcagno A, Lucchini A, Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. Journal of Infection 2008; 57: 78- 81. Impact factor 2008: 3.089;

154. González de Requena D, Bonora S, Castagna A, Hasson H, Marucco Aguilar D, D'Avolio A, Sciandra M, Trentini L, Calcagno A, Lazzarin A, Di Perri G. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. J Antimicrob Chemother. 2008;62(2):384-7. Impact factor 2008: 4.328;

155. González de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. Antimicrob Agents Chemother. 2008; 52(3):1066-71. Impact factor 2008: 4.716;

156. Bonora S, Calcagno A, Fontana S, D'Avolio A, Siccardi M, Gobbi F, Di Perri G. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. Clin Infect Dis. 2007; 45(12):1654-5. Impact factor 2007: 6.750;

157. Aguilar Marucco D, Veronese L, de Requena DG, Bonora S, Calcagno A, Cavecchia I, Sinicco A, De Rosa FG, Cariti G, Di Perri G. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. J Antimicrob Chemother 2007; 59: 565- 568. Impact factor 2006: 4.038.

158. González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. Unexpected drug-druginteraction between tipranavir/ritonavir and enfuvirtide. AIDS. 2006; 20(15):1977-9. Impact factor 2006: 5.632;

159. Garazzino S, Tettoni M, Calcagno A, D'Avolio A, Bonora S, Di Perri G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases.  J Antimicrob Chemother 2006;58: 483- 485. Impact factor 2006: 3.891;

160. Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G. Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors. Infez Med 2006; 14: 61-70.